Cancer: The effects of ± treatment of distant metastasis with the treatment of phosphons

Endocrine therapy resistance is the main cause of long-distance recurrence (DR) of hormone-positive breast cancer.
study aims to compare differences in survival rates after distant recurrence in patients receiving different complementary endocrine treatments in the BIG 1-98 trial.
BIG 1-98 trial compared the five-year effect of complementary therapy in four therapeutic arms: tymoxifen (T), lysol (L), tymoxifen →RL), and phosphonphetium →LT).
8.1 years of medium follow-up, 911 patients in 8010 patients (302 cases in Group T, 285 cases in Group L, 170 cases in Group TL and 154 cases in Group LT) relapsed for the first time.
characteristics associated with survival after distant recurrence are determined by single-variable and multivariable Cox analysis.
59 months after a distant recurrence (quarter range: 29-88 months).
of all patients with distant recurrences, 38.1% were registered as 65 years of age or older, 61.9% had tumors greater than 2 cm, and 69.7% had positive lymph nodes.
35.6% of patients received new complementary or complementary chemotherapy.
there was no significant difference in survival after distant recurrence in the treatment group (medium survival: T group 20.8 months, Group L 17.9 months, TL group 17.3 months, LT group 20.8 months; P-0.21).
multi-factor analysis showed that older (risk ratio of 1.35; 95% CI 1.15-1.59), tumor diameter greater than 2 cm (HR 1.19; 95% CI 1.00-1.41), and more than 4 positive lymph nodes (HR Patients with 1.31;95% CI 1.05-1.64), progesterone lice (PR) negative (HR 1.25; 95% CI 1.02-1.52) or shorter disease-free survival (DFS) had significantly poor prognosis for survival after distant recurrence.
, there was no significant difference in survival rates after distant metastasis in breast cancer patients, between tymoxifen, lysole, or these two drug sequentia-assisted treatments.
age, primary tumor size, lymph node-positive number and progesterone-like status, as well as DFS, all have significant effects on survival rates in such patients, suggesting that traditional baseline high-risk characteristics can still be used as prognostic indicators in metastatic breast cancer.
。